Skip to content

Press Release · Press Releases · United States

Lupin Launches Raltegravir Tablets, USP, 600 mg in the United States

Issued by PR Newswire

Image: PR Newswire

As the First-To-File, Lupin is Eligible for 180-Day Generic Exclusivity MUMBAI, India and NAPLES, Fla., Nov. 3, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

Sempra Reports Strong Third-Quarter 2026 Results

Advancing 2026 Value Creation Initiatives Updating 2026 GAAP EPS guidance range Guiding to high-end of 2026 adjusted EPS guidance range Announcing expected 20% increase to Oncor's base capital plan SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Sempra (NYSE: SRE) today reported third-quarter...

PR Newswire ·